Although an increase in non-HDL-C was statistically associated to increased CIMT in univariate analysis only (Table 1) , it appears necessary to reach the non-HDL-C goal after the LDL-C goal in HIV+ patients who are generally exposed to multiple CV risks and predisposed to increased atherosclerosis 6 -The first three sentences were modified according to the reviewer's request as follows:
"The introduction of combined antiretroviral therapy (c-ART) has significantly increased the survival rates of HIV-positive (HIV+) patients and has improved their quality of life 1 . However emergence of cardiovascular (CV) complications related to HIV infection per se and/or to c-ART has raised clinical and public health concerns [2] [3] [4] [5] given the increasing duration of exposure to c-ART. Several classical CV risk factors including age, gender, body mass index (BMI), blood pressure, increased total cholesterol (TC) levels or tobacco consumption have been previously recognized in HIV+ patients 6 . Surprisingly, there are contradictory reports on the association between low density lipoprotein cholesterol (LDL-C), the most recognized lipid risk factor in non-HIV populations 7 , and CIMT in HIV+ populations [8] [9] [10] [11] .
7. Eisenberg DA et al Am J Med 1998.
-The reference corresponding to the LT definition was added in the sentence 7. -The fourth sentence was corrected by changing "formed" to "selected" as suggested.
Austin et al
-The asterix were used as indent and was now changed to appropriate indent.
-We totally agree with the referee that fibrate treatment was not mentionned in the NCEP-ATPIII definition of metabolic syndrome. We now specified the criteria of diagnosis in agreement with the original definition and added this sentence in the text (page 6) "In addition, patients treated by hypertensive medication were categorized as having high blood pressure, and patients receiving fibrate treatment were considered as having TG
1.5 g/l." (page 6)
In this study, 7 patients were categorized as MS on the basis of these medications.
-In the first manuscript, no adjustment was performed, so we are now providing adjusted p values for age, gender and tobacco consumption. Because this multivariate model produces less statistical relationship between lipid parameters and CIMT, results and discussion section were modified in this revised manuscript.
Results section :
-There is no type setting error concerning duration of antiretroviral therapy. Perhaps, NNRTI duration is low because this is a "old" cohort recruited in 1999 and there were fewer
NNRTIs available than today.
-The first sentence of the second paragraph was modified as requested to include "in the general population":
-The asterix were removed and replaced by indents.
-The second sentence of section 3 was corrected as requested by adding "compared to the absence of MS".
-The first sentence of paragraph 4, section 3 was divided in two pieces in order to simplify the reading as follows: "Beyond hypertriglyceridemia and low HDL-C levels, patients with MS compared to those without had significant increase in non-HDL-C and apoB levels, whatever the definition used. The lipid profile of patients with the MS was also characterized by decreased apoA1 levels and LDL size when compared to patients without MS while TC and LDL-C were similar (Table 3) ".
-The next sentence, was modified as suggested: "There was no difference in inflammation markers including hs-CRP, albumin and prealbumin levels according to the presence or absence of the MS (Table 3) ".
Reply to observations of reviewer 3
First and all, we take the opportunity to thank the reviewer for his helpful comments to improve our manuscript.
1. Among the entire SUPRA cohort of 423 patients, only 232 patients were selected in this sub-study on the basis of available frozen aliquots stored at -80°C. For all non-studied patients the restriction factor was the volume of frozen sample. Hopefully, this selection did not lead to bias as there was no significant difference between the characteristics of patients for this subgroup compared to the remaining of cohort. This was noted in the study design as with TG levels 4.5 mmol/l, whose measurements did not allow the LDL-C calculation"
(page 11).
3. We totally agree with the referee that fibrates and hypertensive medications were not In this study, 7 patients were defined as having a MS on the basis of an hypertensive/or fibrate treatment. . Surprisingly, there are contradictory reports on the association between low density lipoprotein cholesterol (LDL-C), the most recognized lipid risk factor in non-HIV populations 7 , and CIMT in HIV+ populations [8] [9] [10] [11] . Because classical risk factors do not account for all atherosclerosis risk in HIV+ patients, a search for non-classical could be of interest. Some of them could be directly related to HIV infection or its treatment such as duration of c-ART, time from HIV diagnosis, HIV plasma viral load or lipodystrophy [12] [13] [14] [15] . Other ones including non-high density lipoprotein (HDL) cholesterol, Triglyceride (TG) to HDL ratio, apolipoprotein B (apoB), LDL size, inflammation or oxidative stress could be related to metabolic disorders such as metabolic syndrome (MS) and lipid triad (LT). LT defined as low HDL-C, high TG and small dense LDL presence 16 represents the characteristic dyslipidemia of MS. In order to evaluate non classical CV risk factors, we studied firstly the relationship between CIMT and biological parameters (lipids, inflammation and oxidative stress markers); then the relationship between CIMT and metabolic cluster (MS, LT) presence.
Patients and methods

1-Study design
This ancillary study was performed on 232 HIV+ patients from the SUPRA . In addition, patients treated by hypertensive medication were categorized as having high blood pressure, and patients receiving fibrate treatment were considered as having TG ≥1.5 g/l.
-According to the International Diabetes Federations (IDF) criteria, MS was defined on the presence of an increased waist circumference: ≥ 94 cm for men, ≥ 80 cm for women, associated with two or more of the following criteria: fasting glucose ≥ 1.0 g/l (5.6 mmol/l) and/or medication; previously diagnosed type 2 diabetes; triglycerides ≥ 1.5 g/l or specific treatment; HDL-C < 0.4 g/l for men, <0.5 g/l for women or specific treatment; blood pressure ≥ 130/85 and/or medication 26 .
-LT was defined as the combination of three lipid disorders that are TG levels ≥ 1.5g/l, HDL-C < 0.4 g/l for men, < 0.5 g/l for women, and LDL size < 25.5 nm
16
. 
5-Statistical analysis
Results
1-Clinical and immuno-virological characteristics of patients
In this sample of 232 patients, mean age was 41 ± 9 years, 75% were male, 70% were 
2-Relationship between biological parameters and CIMT
8
Increased TC, non-HDL-C, apoB levels and TG/HDL ratio were significantly associated with a 0.05 mm increase in CIMT when comparing the highest quartile against the lowest one in univariate analysis (Table 1) . After adjustment on age, gender and tobacco consumption, these relationships disappeared but it remained a trend toward significant association between TG/HDL molar ratio>1.5 and CIMT (p=0.08). LDL size, that was negatively correlated with TG levels (r=-0.37 p<10 
3-Metabolic and biological clusters -Metabolic syndrome
Prevalence of the MS was 7.3% (n=17) using the NCEP-ATP III definition and 11.2%
(n=26) with the IDF criteria.
The presence of MS was associated with a significant increase in CIMT compared to absence of MS, whatever the definition used, in univariate and multivariate analysis ( Beyond hypertriglyceridemia and low HDL-C levels, patients with MS compared to those without had significant increase in non-HDL-C and apoB levels, whatever the definition used.
The lipid profile of patients with the MS was also characterized by decreased apoA1 levels and LDL size when compared to patients without MS while TC and LDL-C were similar (Table 3 ). There was no difference in inflammation markers including hs-CRP, albumin and prealbumin levels according to the presence or absence of the MS (Table 3) . As protein oxidation marker, AOPP levels were significantly increased in patients with the MS compared to those without. Because comparison of biological parameters between patients with or without MS defined by NCEP or IDF criteria was similar for all parameters, data are not shown for IDF definition.
-Lipid Triad
Mean CIMT was similar (0.60±0.13 vs 0.57±0.10 mm, p=0.14) in presence and absence of the LT defined as the combination of TG ≥ 1.5g/l, HDL-C < 0.4 g/l for men, < 0.5 g/l for women, and LDL size < 25.5 nm (Table 2) .
Patients with the LT (n=43, prevalence of 19%) were statistically more prone to have lipodystrophy (58.1 vs 32.8 %, p<0.01) and to receive PI (65.1 vs 45.5%, p<0.05) when compared to patients without the LT.
Beyond lipid disturbances included in the LT definition, TC, non-HDL-C and apoB levels were significantly higher while apoA1 levels were lower in patients with the LT compared to those without. Similarly to the MS, there was no significant difference in LDL-C levels with regard to the LT presence (Table 4) . Interestingly, there was no statistical difference in insulin levels, HOMA levels or prevalence of insulin-resistance defined as HOMA index >4 in relation to the LT presence or absence (Table 4) . Moreover, no association of the LT with inflammation markers including hs-CRP, albumin and prealbumin levels was observed (Table 4 ). Likewise to the MS, significant elevated AOPP levels were associated with the presence of the LT (p<10 -4 ).
Discussion
In this study, we demonstrated that non-HDL-C, apoB or TG/HDL ratio are stronger predictive factors of increased CIMT than LDL-C in HIV+ patients, in univariate analysis, while after adjustment on age, sex and smoking habits, TG/HDL ratio >1.5 appeared as an interesting determinant of subclinical atherosclerosis. These results were in agreement with previous data in the general population reporting a higher predictive value of non-HDL-C than LDL-C in CV risk assessment 27 . In addition, metabolic cluster disturbance such as MS presence was associated with increase in CIMT, while LT was not.
Non-HDL-C increase, closely linked to increased TG/HDL ratio, appears as a result of abnormal lipoprotein metabolism characterized by increased production of VLDL and/or delayed clearance of VLDL, as frequently observed in diabetes type II patients 28 and in HIV+ patients [29] [30] [31] . Classically, VLDL accumulation is associated to new lipid exchange pathways 11 leading to decrease in LDL size and HDL-C levels 32 . This combination of elevated serum TG, decreased HDL-C and LDL size constitute the LT 33 , an atherogenic risk factor in the general population 16 . Surprisingly, the LT presence was not associated to increased CIMT in our HIV cohort, suggesting a worse role of VLDL per se. In addition, mechanism of VLDL accumulation in HIV+ patients appears more complex than in diabetes type II patients where insulin-resistance plays a central role 34 . Indeed, there was no association between the LT and HOMA index in the present study (See Table 4 ), by contrast with the frequent occurrence of LT in insulin resistance state in the general population 33 . This independence between dyslipidemia and insulin disorders, previously observed in some HIV+ patients 31, 35, 36 could be related to recent evidence of a direct effect of decreased adiponectin level on VLDL clearance 37, 38 .
The significant relationship between apoB and CIMT underlined the atherogenicity of all apoB-containing lipoproteins (IDL, VLDL, LDL), but increased VLDL particles seems to represent the major atherogenic lipid factor in HIV+ patients. Indeed, no relationship was observed between LDL-C levels and CIMT, even in univariate analysis, while LDL-C was correlated with apoB. Although LDL-C was determined by the use of Friedwald's formula, it is unlikely that the relationship between LDL-C and CIMT has been skewed, as there were only nine patients (3.9%) with TG levels ≥4.5 mmol/l, whose measurements did not allow the LDL-C calculation. VLDL atherogenicity could be related to its ability to infiltrate the intimamedia space when endothelial permeability is altered, leading to their uptake by the macrophage via a VLDL receptor, thus accelerating the formation of foam cells Although an increase in non-HDL-C was statistically associated to increased CIMT in univariate analysis only (See Table 1 ), it appears necessary to reach the non-HDL-C goal after the LDL-C goal in HIV+ patients who are generally exposed to multiple CV risks and predisposed to increased atherosclerosis 6, [8] [9] [10] 12 . A particularity of dyslipidemia in HIV+ patients treated by c-ART is the combination of lipid disturbances related firstly to the HIV infection per se and secondly induced by c-ART. Management of this complex dyslipidemia appears as an important challenge for clinicians, as often, lipid lowering therapy alone does not allow to reach the lipid target 36, 41, 42 and should be associated to diet and lifestyle modification and/or switching of some antiretroviral agents 43 . A specific disturbance that persists in about half of patients is a trend to low HDL-C levels and moderate hypertriglyceridemia. In this context, the determination of a TG/HDL cut-off associated to a significant sub-clinical atherosclerosis presence appears as a useful tool for clinicians. The TG/HDL molar ratio was previously reported as a marker of LDL size with a cut-off at 1.3 for identifying diabetic patients having small dense LDL 44 . In addition to a significant linear correlation between TG/HDL ratio and LDL size (r=-0.36 p<10 -4 ) observed in our study, a value of 1.5 was identified as the significant cut-off for distinguishing HIV+ patients having higher CIMT. Furthermore, other studies such as the DAD collaboration reported an 13 independent effect of dyslipidemia on myocardial infarction in HIV+ patients underlining the need to analyse more deeply those lipid abnormalities 45 .
The MS is recognized as a clinical condition associated with an enhanced risk of CV diseases 46 . To identify MS, NCEP-ATP III criteria is the most frequently used classification, while a more recent definition was provided by the IDF, leading to some difference in MS prevalence 47 . This latter definition was reported to select more patients than NCEP which were characterized by less insulin-resistance and lower CIMT 48 . In our study, prevalence of MS was indeed higher with IDF (11.2%) than with NCEP-ATP III criteria (7.3%) and HOMA index > 4 was more frequent when using NCEP-ATP III rather than IDF definition for MS (64.7% and 53.8% respectively). The statistical significant association between the MS presence and increase in the CIMT was similar whatever the definition used, in univariate and multivariate analysis ( Table 2 ). This observation was in agreement with recent data reporting a significant association between increased common CIMT and MS presence, while internal CIMT was similar in patients with and without MS 49 , a result that could be due in part to the lesser variability of common CIMT measurement. In our study, CIMT was measured only on the left far wall carotid arterial in order to obtain more interpretable findings for all patients, but the bulb or the internal carotid was not explored. .
In the general population, MS is associated with inflammation and oxidative stress markers that contribute to the increased atherosclerosis risk 55, 56 . In our study, presence of MS was not associated with inflammation markers including hs-CRP, albumin and prealbumin levels, in contrast to a previous report in HIV+ populations 51 . There was also no association of MS with oxidative stress marker, excepting an increase in AOPP levels. It should be underlined that this absence of relationship between MS and inflammation or oxidative stress parameters could be related to the low prevalence of MS in this cohort of limited size.
A main limitation of this study is its cross-sectional design. Further prospective studies could be conducted to determine the capacity of non-HDL-C, apoB, or TG/HDL ratio for predicting progression of CIMT and occurrence of cardiovascular events in larger cohort of HIV+ patients.
In conclusion, considering the stronger relationship between CIMT and non-HDL-C, apoB, or TG/HDL ratio than with LDL-C, and the higher risk of cardiovascular events in HIV+ population cumulating multiple cardiovascular risk factors 9, 57 , reaching non HDL-C goal defined by the NCEP-ATP III and the ACTG/IDSA lipid guidelines appears necessary to 15 manage CV risk beyond beneficial intervention on other modifiable factors such as tobacco 
